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How varying CD4 criteria for treatment initiation 
was associated with mortality of HIV-patients? 
A retrospective analysis of electronic health 
records from Andhra Pradesh, India
Background HIV treatment and care services were scaled up in 2007 in In-
dia with objective to increase HIV-care coverage. CD4 count based criteria was 
mainly used for treatment initiation with increasing threshold in later years. 
Therefore, this paper aimed to evaluate the survival by varying CD4 criteria for 
antiretroviral treatment (ART) initiation among of HIV-positive patients, and 
independent factors associated with the mortality.
Methods This retrospective cohort study included 127 949 HIV-positive pa-
tients aged ≥15 years, who initiated ART between 2007 and 2013 in Andhra 
Pradesh state, India. The patient’s demographic and clinical characteristics 
were extracted from the patient’s health records from electronic Computerized 
Management Information System Software (CMIS). Incidence of mortality/100 
person-years was calculated for CD4 and treatment initiation categories. Ka-
plan-Meier and multivariable Cox-regression analyses were used to explore 
the association.
Results Median CD4 count was 172 (inter-quartile range (IQR) = 102-240) at 
the time of treatment initiation, and 19.3% of them had ≤ 100 CD4 count. In-
cidence of mortality for the period 2007-08 (CD4 ≤ 200 cells/mm3) was 8.5/100 
person-years compared to 6.4/100 person-years at risk for the period 2012 on-
wards (CD4 ≤ 350 cells/mm3). Earlier thresholds for treatment initiation showed 
higher risk of mortality (2007-08 (CD4 ≤ 200 cells/mm3), adjusted hazard ratio 
(HR): 1.86, 95% confidence interval (CI): 1.68-2.07; 2009-11 (CD4 ≤ 250 cells/
mm3), HR = 1.67, 95% CI = 1.51-1.85) compared to 2012 onwards (CD4 ≤ 350 
cells/mm3) criteria for treatment initiation.
Conclusions Increasing CD4 threshold for treatment initiation over time was 
independently associated with lower risk of mortality. More efforts are required 
to detect and treat early, monitoring of follow-ups, promote health education to 
improve ART adherence, and provide supportive environment that encourages 
HIV-infected patients to disclose their HIV status in confidence.
Electronic supplementary material: 
The online version of this article contains supplementary material.
journal of
health
global
© 2020 The Author(s)
JoGH © 2020 ISGH
India formed an AIDS Task Force under the Indian Council of Medical Research 
(ICMR) to respond HIV/AIDS challenge after the detection of first AIDS case in 
1986 [1]. Since then, HIV infections have been reported in all states and union 
territories. Further, to manage the HIV programme and its implementation, an 
autonomous National AIDS Control Organisation (NACO) was set up under the 
ministry of Health [2]. India launched a free antiretroviral treatment (ART) pro-
gramme in 2004, and more than 400 ART centres are providing HIV care across 
the nation [3,4].
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The ART services were scaled up at national level in 2007 with objective to increase HIV-care coverage. 
A new treatment criterion (CD4 count ≤ 200 cells/mm3 or HIV clinical stage III/IV irrespective of CD4 
count, including coinfections such as tuberculosis) for ART initiation was adapted [5]. The CD4 criteria 
for ART initiation was further modified in 2009 to ≤ 250 cells/mm3 and to ≤ 350 cells/mm3 in 2012, as rec-
ommended by the Joint United Nations Programme on HIV/AIDS (UNAIDS) [6]. Addition to treatment, 
ART centres also facilitate follow-up monitoring, screening for opportunistic infections, and counselling. 
The 2013 World Health organisation (WHO) ART guidelines strongly recommended initiating ART for 
all adults PLHIV with a CD4 count ≤ 500 cells/mm3, regardless of WHO clinical stage [7]. Early start of 
ART is associated with reduced risk of AIDS progression or death, TB, other coinfections and increased 
likelihood of immune recovery [8-10]. Additionally, evidence from a randomized controlled trial indi-
cated that earlier ART can significantly reduce the risk of HIV to HIV-negative sexual partners in hetero-
sexual couples [11]. The WHO database suggests nearly two-third (60%) of the fifty-eight HIV-focused 
countries had adopted the CD4 threshold of ≤ 500 cells/mm3 for initiating ART, and 7% moved the CD4 
threshold to >500 cells/mm3 by June 2014 [12]. Although the median CD4 count at the time of ART ini-
tiation is progressively increasing, however, it remained significantly lower than 350 cells/mm3 in almost 
all settings [13,14]. Despite the considerable increase in the number of PLHIVs in India accessing ART 
from 17% in 2007 to 52% in 2013, ART coverage of people eligible for treatment is still low [6,15]. The 
success of the ART program depends upon proper monitoring for drug adherence, timely presentation 
and CD4 investigation, as well as motivation for pre-ART cases for on-time visits to the nearest ART cen-
tre for their further assessment to prevent the progression and transmission of HIV [6,12-17].
Several single centre-based studies have been conducted in India to look for demographic and clinical 
factors (such as higher age, male gender, clinical staging III/IV, lesser bodyweight, and low CD4 count 
etc.) associated with the early mortality [18-21]. However, limited studies have been published at the state 
level from India to reconfirm these factors. Therefore, the main objective of this study was to explore the 
survival by varying CD4 criteria of treatment initiation, and the secondary objective was to explore the 
independent factors associated with the mortality.
METHODS
Study Design, period and inclusion
This retrospective analysis included all registered adult (aged ≥ 15 years) HIV/AIDS patients, who initi-
ated ART treatment between January 2007 and December 2013 in undivided Andhra Pradesh state. The 
patient’s demographic and clinical characteristics were extracted from the patient’s health records from 
electronic Computerized Management Information System Software (CMIS). We excluded data from the 
analysis if the patient initiated their treatment elsewhere and registered in Andhra Pradesh, pre-ART cases, 
ART initiation date was missing, ART started in Andhra Pradesh but later transferred out to other states, 
and if the status was unknown at the end of the study period.
State profile
Andhra Pradesh (undivided; as it was divided into Andhra Pradesh and Telangana in 2014) is one of the 
highly populated southern region state in India. According to the national Census 2011, Andhra Pradesh 
had 84.6 million population, with a total area of 275 045 km2 and population density of 308/km2, litera-
cy rate of 67% (male: 74.9%; female: 58.7%), and the sex ratio of 993 females per 1000 males. Adminis-
tratively, Andhra Pradesh was divided into 23 districts that further divided into 1127 revenue divisions. 
The state has a vast network of public health facilities, including 20 district hospitals, 56 area hospitals, 
117 community health centres, 10 specialty hospitals, and 25 civil dispensaries [22].
The HIV detection, treatment and burden in Andhra Pradesh
As of December 2014, the state had 1869 integrated and counselling testing centres (ICTCs), including 
prevention of parent-to-child treatment (PPTCT) centres, 286 government recognized blood banks, and 
274 sexually transmitted disease (STD) clinics [23]. There were 56 ART and 161 Link ART centres func-
tional in the state providing free first and second line HIV treatments. The state also had 40 community 
care centres (CCCs) with the primary duty of counselling to HIV-patients and motivating them to enrol 
to the HIV programme [3,23]. ART centres primarily located at district hospitals and Link ART centres at 
sub-district level. According to 2012 estimates, Andhra Pradesh had the second highest HIV prevalence 
CD4 criteria for treatment initiation and mortality of HIV-patients
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(0.75%) in the age group of 15-49 years after Manipur state (1.22%); however, declined from the 2007-
08 estimate. It remained one of the six high prevent states in India with the highest number of PLHIVs 
(n=419 000) accounting for nearly 20% of total HIV/AIDS cases in the country. The estimated cumulative 
deaths due to AIDS-related illnesses were highest in Andhra Pradesh (approximately 31 000) in 2011 that 
declined from 46 000 deaths in 2007 [3,23].
Enrolment of patients to HIV care
Once an HIV-positive individual reached to an ART centre with an ICTC report, s/he were registered in 
the pre-ART register for HIV care. Furthermore, demographic details and other relevant information were 
also recorded in the patient treatment record (also called White Card) and a Green Book was issued. Pa-
tients were advised to enrol at the nearest ART centre to their current place of residence to ensure prop-
er adherence to treatment. S/he was re-counselled for implications of being HIV-positive, availability of 
treatment, positive living, nutrition, and positive prevention, etc. The early testing of their spouse/part-
ner and children was encouraged. Recently detected persons were kept under the supervision of a care 
coordinator to determine whether a HIV-positive person was treated in the same manner as any other 
patients at the centre, without any discrimination. Furthermore, the patient was referred to a concerned 
doctor who conduct a detailed medical examination for WHO clinical staging, opportunistic infections 
(OIs) and other relevant clinical examinations. Based on the clinical findings, the HIV treatment was initi-
ated as per the NACO guidelines described in the Table S1 in the Online Supplementary Document [5].
Follow-ups and primary event
The primary event of interest was the death of the patients. The date of death for all HIV-infected patients 
who died from all causes during the study period while on antiretroviral treatment was recorded. Patients 
missing their follow-up visits for more than three months were counted as lost to follow-up, and the date 
of the last registered follow-up visit was recorded as the date of follow-up loss. ART for HIV-infected pa-
tient who were transferred to another ART centre were recorded as transferred-out cases, and their dates 
of transfer-out were also recorded. Similarly, patients received medical advice was recorded as on medical 
advice and their dates of medical advice were also recorded [5].
Study variables
Patients’ baseline demographic, program-related information and clinical characteristics data were col-
lected. Baseline demographic characteristics included, age (15-24 years, 25-34 years, 35-44 years, and 
>45 years), sex (male/female), education (no formal education and formal education), marital status (sin-
gle/married), and employment (employed or not employed). Time-period was divided according to the 
CD4 criteria for treatment initiation (ie, ≤200 cells/mm3 in 2007-2008, ≤ 250 cells/mm3 in 2009-2011 
and ≤ 350 from 2012 onwards). The HIV surveillance program-related information included date of ART 
initiation, follow-up status, and last date of ART centre visit. Clinical characteristics at the time of ART 
initiation included bodyweight (< 45 kg, 45-60 kg and > 60 kg), WHO clinical stage (I, II, III, and IV), 
and CD4 count (<100 cells/mm3, 101-200 cells/mm3, 201-250 cells/mm3, 251-350 cells/mm3, 351-500 
cells/mm3 and >500 cells/mm3). We presented missing data as a separate category in each variable and 
did not impute any value to figure out their characteristics. Imputation was not considered sensible in 
this case as data were unlikely to be missing at random.
Statistical analysis
The data were summarised numerically, in the form of percentages for categorical variables. Mean ± stan-
dard deviations (SD) or median with interquartile range (IQR) were used to present quantitative data. 
Mortality density per 100 person-years was calculated for various CD4 categories and ART criteria years. 
The Kaplan-Meier (KM) method was used to estimate survival after ART initiation, and the log-rank test 
was used to determine statistical differences between survival rates in subgroups of the variable [24,25]. 
Univariable and multivariable Cox-regression analytical methods were applied to model predictors of 
mortality following treatment initiation [26]. The unadjusted and adjusted hazard ratios (HRs) with 95% 
confidence intervals (CIs) were estimated. We evaluated departure from the proportional hazard assump-
tion for Cox-regression by tests of Schonefild’s residual and graphical inspection of log-log plots, and all 
the predictor variables satisfied the criterion of being asymptotic [24]. Data were analysed using Stata for 
Windows (version 14.0, StataCorp, College Station, TX, USA) software. The two-sided P-value <0.05 was 
considered as the level of significance.
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Data access permission and ethical statement
Individual level anonymised PLHIV data access permission was granted by NACO for undivided Andhra 
Pradesh under a data sharing scheme with national data analysis plan (NDAP) at phase I for policy mak-
ing in high prevalent states (vide letter No. z-19019/1/2013-NACO(SIMU)). Data were made available to 
the first author for his PhD research by NACO for secondary data analysis, and it has been approved by 
the internal ethics committee. Individual consent was taken the affiliated organisations of NACO during 
the data collection and therefore, no additional consent was required in this study.
RESULTS
Patient characteristics
The baseline patient characteristics according to treatment initiation (based on CD4 criterion) of adult 
HIV-positive patients on ART are summarised in Table 1. Overall, 14.4% deaths were recorded during 
the study period with high proportion within the first year of treatment start (84.8%; 15 566/18,362). 
Reported lost to follow up was 17.9% during 2007-08 that significantly decreased (P < 0.01) to 6.9% in 
2012 onwards. The median age was 34 years, 45.9% females, 45.7% had formal education, 59.4% were 
employed and 68% were married. The median CD4 count was 172 (IQR 102-240) cells/mm3 at the time of 
ART initiation that consistently increased over time (Figure S1 in the Online Supplementary Document).
Table 1. Demographic and clinical characteristics of HIV positive patients on antiretroviral treatment registered during 2007-11 in 
undivided Andhra Pradesh, India
Background profile included in the anal-
ysis (n = 127 949) period of treatment criterion for initiation Based on cd4 count
2007-08 
(n = 39 542)
2009-2011 
(n = 79 776)
2012 onwards 
(n = 8631)
Patient characteristics
Age (in years) at ART initiation, median (IQR) 34 (29-40) 33 (28-39) 35 (29-40) 33 (28-40)
Female, (n, %) 58 677 (45.9) 16 929 (42.8) 36 902 (46.3) 4846 (56.1)
Patients who had formal education, (n, %) 58 462 (45.7) 19 528 (49.4) 35 292 (44.2) 3642 (42.2)
Currently working, (n, %) 75 989 (59.4) 28 530 (72.2) 42 898 (53.8) 4561 (65.8)
Body-weight <45 kg at the time of ART initiation, (n, %) 42 327 (33.1) 13 232 (33.5) 26 831 (33.6) 2264 (26.2)
Married/ cohabiting, (n, %) 87 057 (68.0) 27 128 (68.6) 53 752 (67.4) 6177 (71.6)
CD4 cell count (cells/mm3) at the time ART initiation, median (IQR) 172 (102-240) 144 (85-204) 178 (107-242) 278 (200-333)
CD4 count category (cells/mm3), (n, %):
≤100 24 705 (19.3) 98,58 (24.9) 14 340 (18.0) 507 (5.9)
101-200 37 029 (28.9) 13 491 (34.1) 22 213 (27.8) 1325 (15.4)
201-250 17 849 (14.0) 4517 (11.4) 12 301 (15.4) 1031 (11.9)
251-350 12 512 (9.8) 2212 (5.6) 7058 (8.8) 3242 (37.6)
351-500 5189 (4.1) 982 (2.5) 3549 (4.4) 658 (7.6)
501+ 4264 (3.3) 701 (1.8) 3067 (3.8) 496 (5.7)
Missing 26 401 (20.6) 7781 (19.7) 17 248 (21.6) 1372 (15.9)
WHO clinical stage at the time of ART initiation, (n, %):
I 19 293 (15.0) 3613 (9.1) 12 802 (16.0) 2878 (33.3)
II 50 066 (39.1) 12 952 (32.8) 33 702 (42.2) 3412 (39.5)
III 37 173 (29.1) 14 797 (37.4) 21 505 (27.0) 871 (10.1)
IV 3524 (2.8) 1309 (3.3) 2116 (2.7) 99 (1.1)
Missing 17 893 (14.0) 6871 (17.4) 9651 (12.2) 1371 (15.9)
Program context
Number of ART centres 56 31 45 56
Number of districts covered 25 22 23 25
Number of people registered for ART 291 151 103 946 187 205 -*
Recorded adherence (≥95%) to ART, (%) 89.5 90.3 89.3 86.8
Total recorded deaths, (n, %) 18 362 (14.4) 7061 (17.9) 10 902 (13.7) 399 (4.6)
Deaths within 1st year of ART start, (n, %) 15 566 (12.2) 5618 (14.2) 9563 (12.0) 385 (4.5)
Recorded lost to follow up, (n, %) 16 536 (12.9) 6992 (17.7) 8953 (11.2) 591 (6.9)
ART – antiretroviral treatment
*All these HIV-patients were registered between 2007 and 2011.
CD4 criteria for treatment initiation and mortality of HIV-patients
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Person-years and survival analysis
The study cohort contributed a total of 208 301 person-years at risk during the study period as pre-
sented in Table 2. Overall mortality density was 8.8 (95% CI = 8.7-8.9) per 100 person-years at risk. 
The incidence of mortality was reported higher with the ear-
lier treatment initiation periods (8.5 and 11.0 per 100 per-
son-years in 2007-08 and 2009-11 respectively) compared to 
6.4 per 100 person-years from 2012 onwards. The mortality 
incidence was also consistently decreased when CD4 count 
increased (13.2/100 person-years for CD4 ≤ 100 to 2.0/100 
person-years for CD4 > 500). Overall mean survival during 
the study period was 66.7 (95% CI = 66.5-67.0) months and 
significantly different between CD4 subgroups (Figures S2 & 
S3 in the Online Supplementary Document). A twenty-four 
months survival was recorded to 96.1% who started their 
treatment with the CD4 count ≤ 350 cells/mm3 treatment ini-
tiation criteria in 2012 onwards compared to 59.8% survival 
with CD4 count ≤ 200 cells/mm3 criteria in 2007-08 (Figure 1).
Risk of mortality with varying CD4 levels over time
The effect of varying CD4 cell count categories on the risk of dying in first year of treatment initiation 
over time is presented in Table 3. Higher rates of mortality (11.3% to 18.6% for 2007-08 period; and 
11.7% to 21.1% for 2009-11 period) have been reported compared to 6.9%-11.4% from 2012 onwards 
when patient level CD4 count ≤ 200 cells/mm3. Furthermore, multivariable Cox regression was used to 
estimate adjusted hazard ratios for 2007-08 (HR range = 1.04-2.36) and (HR range = 0.64-1.73) 2009-11 
to explored the trend of risk in different CD4 levels compared to 2012 onwards category. This analysis 
clearly indicated higher risk of mortality within the first year of treatment start was associated with old-
er treatment initiation criteria (on average 60% higher risk to 2007-08 and 22% higher risk to 2009-11 
compared to 2012 onwards).
Factors associated with mortality
The unadjusted and adjusted analysis showed the associated predictors of mortality within the first year 
of treatment initiation among adult HIV-infected patients in Table 4. The risk of mortality within the 
first-year of treatment initiation was significantly associated with older age (≥45 years, HR = 1.4, 95% 
CI = 1.27-1.71), male gender (HR = 1.56, 95% CI = 1.51-1.63), with no formal education (HR = 1.16, 95% 
CI = 1.12-1.20) and working by occupation (HR = 1.17, 95% CI = 1.13-1.21). Further, patients with WHO 
clinical stage IV had a 1.67-fold increased risk of mortality compared to those at stage I. The likelihood 
Figure 1. Survival probabilities at 24 months after ART initia-
tion by varying CD4 criteria for treatment initiation.
Table 2. Mortality distribution among the HIV-positive patients who had initiated treatment over time with different treatments criteria
Background variaBles overall deaths 
during study
deaths within  
12 mo (%)
crude mortality rate 
(per 100 registrations)
total per-
son-years at risk
incidence mortality rates per 100 
person-years* (95% ci)
CD4 count (cells/mm3) (across the years)
≤100 5640 4914 (19.9) 22.8 42 657 13.2 (12.8-13.5)
101-200 5117 4222 (11.4) 13.8 62 508 8.2 (7.9-8.4)
201-250 1542 1238 (6.9) 8.6 27 386 5.6 (5.3-5.9)
251-350 804 647 (5.2) 6.4 18 272 4.4 (4.1-4.7)
351-500 204 151 (2.9) 3.9 7504 2.7 (2.3-3.1)
500+ 124 93 (2.2) 2.9 6106 2.0 (1.6-2.4)
Missing 4931 4301 (16.3) 18.7 42 539 11.6 (11.2-11.9)
ART criteria year:
2007-08 (CD4 ≤ 200 cells/mm3) 7061 5618 (14.2) 17.9 82 972 8.5 (8.3-8.7)
2009-11 (CD4 ≤ 250 cells/mm3) 10 902 9563 (12.0) 13.7 99 467 11.0 (9.9-11.2)
2012 (CD4 ≤ 350 cells/mm3) 399 385 (4.5) 4.6 6278 6.4 (5.7-7.0)
Combined 18 362 15 566 (12.2) 14.4 2 871 782 8.8 (8.7-8.9)
ART – antiretroviral treatment, CI – confidence interval
*Calculated as overall deaths divided by total person-years at risk during the study period.
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Table 3. Risk of mortality in the first year of treatment initiation with varying CD4 levels in HIV-positive individuals
patient cd4 levels and year of change in 
eligiBility for treatment percent died within first year unadjusted hr (95% ci) adjusted* hr (95% ci)
CD4 ≤ 100:
2007-08 18.6 1.47 (1.13-1.90) 1.38 (1.06-1.80)
2009-11 21.1 1.67 (1.29-2.17) 1.66 (1.28-2.15)
2012 (ref) 11.4 1 1
CD4 101-200:
2007-08 11.3 1.41 (1.14-1.75) 1.34 (1.08-1.65)
2009-11 11.7 1.47 (1.20-1.82) 1.17 (1.17-1.77)
2012 (ref) 6.9 1 1
CD4 201-250:
2007-08 8.4 1.91 (1.37-2.65) 1.73 (1.24-2.41)
2009-11 6.6 1.52 (1.10-2.30) 1.46 (1.06-2.01)
2012 (ref) 3.8 1 1
CD4 251-350:
2007-08 8.1 2.51 (1.95-3.24) 2.36 (1.81-3.07)
2009-11 5.4 1.68 (1.33-2.12) 1.61 (1.27-2.03)
2012 (ref) 2.7 1 1
CD4 351-500:
2007-08 5.3 1.79 (1.02-3.14) 1.72 (0.97-3.04)
2009-11 2.3 0.77 (0.45-1.31) 0.75 (0.44-1.28)
2012 (ref) 2.4 1 1
CD4 501+:
2007-08 3.1 1.02 (0.51-2.07) 1.04 (0.51-2.12)
2009-11 1.9 0.64 (0.34-1.18) 0.64 (0.35-1.20)
2012 (ref) 2.4 1 1
CD4 – missing:
2007-08 20.8 3.69 (2.95-4.61) 3.53 (2.81-4.41)
2009-11 15.1 2.46 (1.97-3.06) 2.29 (1.84-2.86)
2012 (ref) 5.9 1 1
Ref – reference category, HR – hazard ratio, CI – confidence interval
*Adjusted for socio-demographic (age, sex, education, marital status, and employment) and clinical (bodyweight and WHO clin-
ical stage) characteristics.
of death among those with a baseline CD4 count of ≤ 100 cells/mm3 increased to 9-fold (HR = 9.44, 95% 
CI = 7.78-11.59), compared to the patients with CD4 count >500 cells/mm3.
DISCUSSION
The ART scaling-up service has resulted greater coverage of HIV-patients at the early stages. Our findings 
clearly indicate higher incidence of mortality for earlier treatment initiation criteria – 8.5/100 persons-years 
for 2007-08 period (CD4 ≤ 200 cells/mm3), and 11.0/100 person-years for 2009-11 period (CD4 ≤ 250 
cells/mm3) – compared to 2012 onwards (CD4 ≤ 350 cells/mm3) criteria. Further, the overall excess risk 
of death was 84% (HR = 1.84, 95% CI = 1.66-2.04) for 2007-08 period (CD4 ≤ 200 cells/mm3), and 61% 
(HR = 1.61, 95% CI = 1.46-1.79) for 2009-11 period (CD4 ≤ 250 cells/mm3) compared to 2012 onwards 
(CD4 ≤ 350 cells/mm3) criteria. These findings are in agreement with other studies published from re-
source-limited settings [9,27,28]. An increased level of CD4 count is always linked with a decreased risk 
of a new AIDS event or death [29-31]. Furthermore, a multinational study showed that early start of ART 
could increase life expectancy of HIV-positive persons to the general population [29-32].
Decentralisation of HIV care delivery has increased population coverage and encouraged early access to 
ART centres with lower travel costs compared to hospitals [29,30]. Patients who approach ART centre 
at their early stage could delay complex disease conditions due to convenient and easier access to HIV 
care facility. Therefore, decentralisation of ART services seems to be associated with earlier presentation 
to HIV care, which might provide opportunity to many patients to initiate early treatment during the 
disease progression. Increasing numbers of patients have been shown an inclination to start ART in the 
early stages [4,6].
CD4 criteria for treatment initiation and mortality of HIV-patients
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This retrospective analysis showed 85% of the total deaths have been occurred within the first year of treat-
ment start. This indicates majority of these patients were accessed ART at the later stage of their disease, 
and explained by the fact that more than one-third (38.4%) of these patients had both CD4 cell count 
≤ 200 cells/mm3 and WHO clinical stage III/IV at the time of treatment start. Other Indian [9,16,18,19] 
and international [10,33-36] studies conducted in the other low- and middle-income countries confirmed 
similar findings. Several self-perceived personal (such as service delivery, financial, personal health per-
ception, and logistical) and structural barriers may also play a significant role in delaying ART accessing 
at the earlier stage [37].
The CD4 count is an established indicator of the disease severity that directly related to the functional and 
immune status of a patient, and risk of early mortality among those with lower CD4 counts [38]. Our anal-
ysis also showed higher risk of mortality with CD4 count ≤ 350 cells/mm3. A study in Hong Kong showed 
2.69-fold risk of death when they start treatment with a CD4 count <100 cells/mm3 during the follow-up 
Table 4. Factors associated with mortality after antiretroviral treatment initiation by multivariable Cox regression 
analysis
patient characteristics
within first year of art initiation within the overall study period
Unadjusted HR 
(95% CI)
Adjusted HR 
(95% CI)
Unadjusted HR 
(95% CI)
Adjusted HR 
(95% CI)
Age (categorical):
15-24 (ref) 1 1 1 1
25-34 1.28 (1.19-1.37) 1.22 (1.13-1.30) 1.28 (1.21-1.37) 1.22 (1.14-1.30)
35-44 1.55 (1.44-1.66) 1.39 (1.30-1.49) 1.54 (1.44-1.64) 1.38 (1.29-1.47)
45+ 1.85 (1.72-1.99) 1.57 (1.46-1.69) 1.85 (1.73-1.98) 1.58 (1.48-1.69)
Sex:
Male 1.67 (1.61-1.72) 2.05 (1.97-2.13) 1.69 (1.64-1.74) 2.07 (2.00-2.15)
Female (ref) 1 1 1 1
No formal education 1.10 (1.06-1.13) 1.04 (1.01-1.08) 1.10 (1.07-1.13) 1.06 (1.03-1.09)
Formal education (ref) 1 1 1 1
Marital status:
Single (ref) 1 1 1 1
Married/Live-in 1.02 (0.99-1.06) 0.90 (0.87-0.93) 1.04 (1.00-1.07) 0.90 (0.87-0.93)
Occupation
Working 1.19 (1.15-1.23) 1.18 (1.14-1.22) 1.18 (1.14-1.22) 1.17 (1.13-1.20)
Not working (ref) 1 1 1 1
Weight (kg):
<45 3.82 (3.52-4.15) 4.09 (3.76-4.45) 3.48 (3.23-3.74) 3.83 (3.56-4.13)
45-60 1.86 (1.71-2.02) 1.79 (1.64-1.94) 1.80 (1.67-1.93) 1.75 (1.62-1.88)
61+ (ref) 1 1 1 1
missing 3.15 (2.89-3.44) 3.09 (2.82-3.38) 2.95 (2.72-3.19) 2.98 (2.74-3.24)
Treatment start period:
2007-2008 (≤200 cells/mm3) 2.96 (2.67-3.28) 1.68 (1.51-1.87) 3.11 (2.81-3.44) 1.84 (1.66-2.04)
2009-2011 (≤250 cells/mm3) 2.45 (2.21-2.72) 1.58 (1.42-1.75) 2.43 (2.20-2.69) 1.61 (1.46-1.79)
2012 onwards (≤350 cells/mm3) (ref) 1 1 1 1
CD4 count (cells/mm3):
≤100 10.34 (8.42-12.69) 7.40 (6.02-9.10) 9.01 (7.58-10.82) 6.48 (5.42-7.75)
101-200 5.59 (4.55-6.86) 4.72 (3.84-5.80) 5.11 (4.27-6.10) 4.27 (3.57-5.11)
201-250 3.32 (2.69-4.10) 3.12 (2.52-3.85) 3.13 (2.61-3.76) 2.91 (2.42-3.50)
251-350 2.53 (2.04-3.15) 2.54 (2.04-3.16) 2.44 (2.02-2.95) 2.42 (2.00-2.93)
351-500 1.35 (1.04-1.75) 1.28 (0.99-1.66) 1.37 (1.10-1.72) 1.29 (1.04-1.62)
501+ (ref) 1 1 1 1
missing 8.48 (6.90-10.41) 6.42 (5.23-7.89) 7.48 (6.26-8.94) 5.69 (4.76-6.80)
WHO clinical stage:
I (ref) 1 1 1 1
II 1.14 (1.08-1.21) 0.96 (0.91-1.02) 1.15 (1.09-1.20) 0.97 (0.92-1.02)
III 1.59 (1.50-1.68) 1.19 (1.13-1.26) 1.55 (1.48-1.63) 1.17 (1.12-1.23)
IV 3.32 (3.06-3.59) 2.02 (1.87-2.19) 3.15 (2.92-3.39) 1.96 (1.82-2.11)
missing 1.44 (1.36-1.54) 0.99 (0.92-1.06) 1.42 (1.34-1.50) 0.97 (0.91-1.04)
ART – antiretroviral treatment, HR – hazard ratio, CI – confidence interval, ref – reference category, WHO – World Health Organ-
isation
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period [39]. Additionally, a study in South Korea showed that patients with CD4 cell count <200 cells/
mm3 had about 5-fold higher mortality than did those with ≥ 500 cells/mm3 [35]. The CD4 cell count is 
one of the key predictor of mortality, as confirmed by several other studies [35,36,39] but some of stud-
ies did not show any association with mortality [10,40]. This may be partly explained by the way CD4 
count measured (continuous or categorical), type of categorisation used, and number of events observed 
in different CD4 count subgroups, that could have made it statistically unreliable.
Males were more at risk for HIV-infection who probably acquired it from the high-risk population (such 
as female sex workers) and transmit to their female partner(s). Our findings are similar with other studies 
from under-developed nations [41,42], but not all of them [34,43]. Females are regularly tested during 
the antenatal care visits or when their spouse show any symptoms leading to earlier diagnosis and treat-
ment of HIV, which could be a reason for their decreased risk of mortality. Though, a gender-wise separate 
analysis in the same state indicated an increased risk of death in older females with the advanced clinical 
stages and lower CD4 counts [9]. This could be a result of social discrimination against females, aware-
ness regarding HIV, and no direct health care facilities. Similar pattern was also observed in some previ-
ous studies from resource-limited settings [21,40]. These, differences may vary with geography and social 
structure of the society. Our analysis showed six years of mean survival after initiation of the antiretroviral 
treatment, which is alike with other studies [21,43], although it remains lower than the developed nations 
[8,39]. Possible explanations include a lack of awareness, accessibility of the treatment, and social stigma.
The leading causes of HIV-related deaths are mainly due to immune reconstitution syndrome and op-
portunistic infections. According to a recent report, patients who start their HIV-treatment at late clinical 
stages (such as III/IV) are at an increased risk of dying [6]. Late presentation to HIV care could also be 
related to self-perceived barriers such as service delivery, finance, personal health perception etc. A study 
from South Africa showed forty-four percent participants had at least one barrier and twenty-four per-
cent reported more than three barriers to care that increases excess mortality from fifty percent to eighty 
percent [37]. Late presentation, either at advanced stages of the disease or with very low CD4 counts, is 
alarmingly high in both developing and developed countries [10,21,44]. Delayed testing and presentation 
at HIV care centres is a consequence of the appearance of symptoms, while earlier diagnosis and presen-
tation is the result of self-perceived risk or universal screening. Early disease stage presentation at ART 
centres will benefit to prevent the progression of AIDS complexity and increasing survival.
Limitations
There were several limitations in this study, and results may carefully be interpreted in the light of these 
limitations. The electronic database did not have information on causes of death, details of treatment reg-
imen, incomplete data in several important variables, and opportunistic infections. Although these details 
were routinely entered in the ART registers. Several important variables such as haemoglobin, height and 
other clinical information were dropped from the analysis due to incomplete information in the electron-
ic database. Additionally, lost to follow-up cases were intractable for outcome assessment and may have 
been at increased risk of dying. This study was retrospectively conducted; therefore, limitations of retro-
spective studies were also included in this study.
CONCLUSIONS AND IMPLICATIONS
In conclusion, this study compared the effect varying CD4 criteria for treatment initiation with mortality 
over time in Andhra Pradesh, India. Increased risk of mortality was found to be associated with the ear-
lier CD4 cut-offs (≤ 200 cells/mm3 in 200708, and ≤ 250 cells/mm3 in 2009-11) for treatment initiation 
compared to ≤ 350 cells/mm3 from 2012 onwards criteria. It indicates the requirement of more efficient 
and inclusive HIV programme to respond to the HIV epidemic in the state and country at large. As ma-
jority of the HIV-patients were died within the first year of treatment initiation, indicating more efforts 
are required to detect early, emphasis on regular follow-ups, promote health education to improve ART 
adherence, and provide supportive environment that encourages HIV-infected patients to disclose their 
HIV status in confidence.
CD4 criteria for treatment initiation and mortality of HIV-patients
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